BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18505083)

  • 21. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms.
    Lissoni P
    Ann N Y Acad Sci; 2000; 917():560-7. PubMed ID: 11268384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melatonin as a new possible anti-inflammatory agent.
    Lissoni P; Rovelli F; Meregalli S; Fumagalli L; Musco F; Brivio F; Brivio O; Esposti G
    J Biol Regul Homeost Agents; 1997; 11(4):157-9. PubMed ID: 9582617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol.
    Lissoni P; Pittalis S; Rovelli F; Zecchini S; Casati M; Tremolada M; Pelizzoni F
    J Biol Regul Homeost Agents; 1996; 10(1):27-30. PubMed ID: 9049779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients.
    Lissoni P; Rovelli F; Brivio F; Fumagalli L; Brera G
    In Vivo; 2008; 22(3):397-400. PubMed ID: 18610754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin.
    Lissoni P; Barni S; Ardizzoia A; Paolorossi F; Crispino S; Tancini G; Tisi E; Archili C; De Toma D; Pipino G
    Oncology; 1992; 49(5):336-9. PubMed ID: 1382256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms.
    Lissoni P; Giani L; Zerbini S; Trabattoni P; Rovelli F
    Nat Immun; 1998; 16(1):27-33. PubMed ID: 9789122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2.
    Lissoni P; Ardizzoia A; Tisi E; Rossini F; Barni S; Tancini G; Conti A; Maestroni GJ
    J Biol Regul Homeost Agents; 1993; 7(1):34-6. PubMed ID: 8346714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study.
    Lissoni P; Vigorè L; Rescaldani R; Rovelli F; Brivio F; Giani L; Barni S; Tancini G; Ardizzoia A; ViganĂ² MG
    J Biol Regul Homeost Agents; 1995; 9(4):155-8. PubMed ID: 8844341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
    Lissoni P; Brivio F; Barni S; Tancini G; Cattaneo G; Archili C; Conti A; Maestroni GJ
    Anticancer Res; 1990; 10(6):1759-61. PubMed ID: 2285255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychoneuroendocrine modulation of regulatory T lymphocyte system: in vivo and in vitro effects of the pineal immunomodulating hormone melatonin.
    Vigoré L; Messina G; Brivio F; Fumagalli L; Rovelli F; DI Fede G; Lissoni P
    In Vivo; 2010; 24(5):787-9. PubMed ID: 20952751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melatonin as biological response modifier in cancer patients.
    Neri B; de Leonardis V; Gemelli MT; di Loro F; Mottola A; Ponchietti R; Raugei A; Cini G
    Anticancer Res; 1998; 18(2B):1329-32. PubMed ID: 9615811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
    Lissoni P; Barni S; Tancini G; Mainini E; Piglia F; Maestroni GJ; Lewinski A
    Oncology; 1995; 52(2):163-6. PubMed ID: 7854778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients.
    Lissoni P; Malugani F; Bukovec R; Bordin V; Perego M; Mengo S; Ardizzoia A; Tancini G
    Neuro Endocrinol Lett; 2003; 24(1-2):83-5. PubMed ID: 12743539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone.
    Lissoni P; Malugani F; Bordin V; Conti A; Maestroni G; Tancini G
    Neuro Endocrinol Lett; 2002 Jun; 23(3):255-8. PubMed ID: 12080288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.
    Lissoni P; Barni S; Fossati V; Ardizzoia A; Cazzaniga M; Tancini G; Frigerio F
    Support Care Cancer; 1995 May; 3(3):194-7. PubMed ID: 7655780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin.
    Lissoni P; Tisi E; Brivio F; Ardizzoia A; Crispino S; Barni S; Tancini G; Conti A; Maestroni GJ
    J Biol Regul Homeost Agents; 1991; 5(4):154-6. PubMed ID: 1803863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of interleukin-2-induced thrombocytopenia during the immunotherapy of cancer by a concomitant administration of the pineal hormone melatonin.
    Bregani ER; Lissoni P; Rossini F; Barni S; Tancini G; Brivio F; Conti A; Maestroni GJ
    Recenti Prog Med; 1995 Jun; 86(6):231-3. PubMed ID: 7624582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melatonin and tryptophan circadian profiles in patients with advanced non-small cell lung cancer.
    Hu S; Shen G; Yin S; Xu W; Hu B
    Adv Ther; 2009 Sep; 26(9):886-92. PubMed ID: 19802530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates.
    Barni S; Lissoni P; Cazzaniga M; Ardizzoia A; Meregalli S; Fossati V; Fumagalli L; Brivio F; Tancini G
    Oncology; 1995; 52(3):243-5. PubMed ID: 7715908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer.
    Lissoni P; Meregalli S; Fossati V; Paolorossi F; Barni S; Tancini G; Frigerio F
    Tumori; 1994 Dec; 80(6):464-7. PubMed ID: 7900237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.